drugset / Trial / NCT03991104
SOX-based CRT for Esophageal Cancer.
NaSingle-groupOpen-labelTreatment
Summary
Patients with esophageal cancer that had locally advanced diseases or with unresectable diseases are being asked to participate in this phase I/II study. This phase I/II study is being conducted to determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), and efficacy of IMRT combined with S-1 and Oxaliplatin (SOX) based chemotherapy for unresectable locally advanced esophageal cancer.
Timeline
- Start
- 2019-05-01
- Primary completion
- 2021-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 110 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 120 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 80 mg/m2 | — |